The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.
The report “High Throughput Screening Market is expected to reach USD 29.29 billion by 2027 from an estimated USD 14.95 billion in 2019, at a CAGR of 7.8%.
HTS Market Drivers: –
1Growing Adoption of Open Innovation Models in Pharmaceutical and Biotechnology Companies
2 Government Funding and Venture Capital Investments
3 Increasing R&D Spending
4 Technological Advancements
Download PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950
The report analyzes the global HTS market by product & service, technology, application, end user, and region. On the basis of product & service, the reagents & assay kits segment accounted for the largest share of the global HTS market in 2017. Factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, increasing pharmaceutical R&D, and increased government funding for life science research are driving the growth of this segments.
- Further breakdown of the Rest of APAC high-throughput screening market into Australia, New Zealand, Singapore, and others
- Further breakdown of the Rest of Europe high-throughput screening market into Belgium, Russia, the Netherlands, Switzerland, and others
The prominent players in the global HTS market are Agilent (US), Danaher (US), Thermo Fisher Scientific (US), PerkinElmer (US), Tecan (Switzerland), Axxam (Italy), Merck Group (Germany), Bio-Rad (US), Hamilton (US), Corning (US), BioTek (US), and Aurora Biomed (Canada).